Clinical Trials Browser

Phase 1 × OTHER × osimertinib × Clear all

NCT04141644 2026-05-19

Osi+Ipi

Phase 1 Active not recruiting

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT05401110 2026-05-07

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04762199 2026-03-31

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT04780568 2025-12-09

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03567642 2025-07-03

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Phase 1 Active not recruiting

Lung Neoplasms

NCT06362980 2024-07-10

EGFR

Phase 1 Recruiting

NSCLC

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Phase 1 Recruiting

Lung Cancer Metastatic

NCT05120960 2024-04-17

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Phase 1 Withdrawn

Brain Neoplasms

NCT04772235 2024-04-03

TOTEM

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03535363 2024-03-13

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT06067776 2023-10-05

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05489731 2023-06-15

VIC-1911

Phase 1 Unknown

Advanced Non-small Cell Lung Cancer

NCT04541407 2023-05-16

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03891615 2020-12-16

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Phase 1 Unknown

Lung Neoplasms

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung